Searched over 200M research papers
10 papers analyzed
These studies suggest that squamous cell carcinoma (SCC) can occur in various body sites with common determinants, has potential for metastasis, and can be influenced by genetic, environmental, and viral factors, with early detection and targeted therapies offering promising treatment options.
20 papers analyzed
Squamous cell carcinoma (SCC) is a type of cancer that arises from squamous cells, which are flat cells found in the skin and the lining of various organs. SCC is one of the most common types of cancer, affecting various parts of the body including the skin, lungs, head, neck, and rectum.
Oral squamous cell carcinoma (OSCC) is a prevalent form of head and neck cancer with a high mortality rate. OSCC has the potential for both regional and distant metastasis. Various potentially malignant disorders, such as leukoplakia and erythroplakia, can transform into OSCC due to common etiological factors like tobacco use, alcohol consumption, and viral infections.
Traditional biopsy remains the gold standard for diagnosing OSCC. However, recent advancements suggest that salivary biomarkers could be utilized for early detection, offering a non-invasive diagnostic alternative.
SCCs are highly heterogeneous tumors that can arise from different epithelial cell populations. Despite their clinical treatment as separate entities, SCCs from various body sites share common genetic and epigenetic determinants. Large-scale genomic studies have identified key mutations and pathways involved in SCC development, such as TP53 mutations and alterations in the PI3K pathway.
Research using mouse models has shown that SCC can originate from different epidermal cell lineages, including hair follicle stem cells and interfollicular epidermis. The development of invasive SCC often requires multiple genetic hits, such as the activation of oncogenic KRas and the loss of tumor suppressor p53.
Lung squamous cell carcinoma (LSCC) is characterized by complex genomic alterations, including a high number of mutations and genomic rearrangements. Key pathways frequently altered in LSCC include the NFE2L2 and KEAP1 pathways, squamous differentiation genes, and the PI3K pathway. These findings highlight potential therapeutic targets for LSCC.
Recent discoveries of genetic abnormalities such as SOX2 amplification and DDR2 mutations have led to the development of targeted therapies for LSCC. These advancements offer new hope for more effective treatments tailored to the molecular profile of the tumor.
HNSCC can arise from multiple anatomic subsites, including the oral cavity, oropharynx, hypopharynx, and larynx. Major risk factors include tobacco and alcohol use, as well as infections with oncogenic viruses like HPV. The incidence of HPV-associated oropharyngeal cancer is increasing, particularly in developed countries.
Early-stage HNSCC is typically treated with either surgery or radiotherapy. For locally advanced cases, a multimodal approach involving surgery followed by adjuvant radiation or chemoradiation is common. For recurrent or metastatic disease, chemotherapy with or without biological agents is indicated.
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. It progresses from precursor lesions like actinic keratosis to invasive and metastatic forms. The American Joint Committee on Cancer has updated staging guidelines to reflect high-risk features and improve prognostic accuracy .
Several histopathologic variants of cSCC are associated with aggressive behavior. Prognostic factors include tumor size, depth of invasion, and perineural involvement. Accurate staging and identification of high-risk features are crucial for effective management.
Squamous cell carcinoma is a diverse group of cancers with varying etiologies, genetic profiles, and treatment approaches. Advances in genomic characterization and the identification of molecular targets are paving the way for more personalized and effective therapies. Early detection through innovative diagnostic methods, such as salivary biomarkers for OSCC, and targeted treatments for specific genetic alterations in LSCC, hold promise for improving patient outcomes across different types of SCC.
Most relevant research papers on this topic